Dupilumab Significantly Improves Patient-Reported Outcomes in Patients Aged Under 12 Years With Atopic Dermatitis: 4-Year Results From the PEDISTAD Registry

Irene Lara-Corrales, The Hospital for Sick Children, Toronto, PQ, Canada; Michele Ramien, Alberta Children's Hospital, Calgary, AB, Canada; Alan D. Irvine, Trinity College Dublin, Dublin, Dublin, Ireland; Lin Ma, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, Beijing, China (People's Republic); Eulalia Baselga, Hospital Sant Joan de Déu, Barcelona, Catalonia, Spain; Marlies de Graaf, University Medical Center Utrecht, Utrecht, Utrecht, Netherlands; Lara Wine Lee, Medical University of South Carolina, Charleston, SC, United States; Joel C. Joyce, Endeavor Health, Skokie, IL, United States; Korey Capozza, Global Parents for Eczema Research, Santa Barbara, CA, United States; Rajan Gupta, Sanofi, Houston, TX, United States; Marius Ardeleanu, Regeneron, Tarrytown, NY, United States; Annie Zhang, Sanofi, Cambridge, MA, United States